SER recommendations on the use of biological drugs in primary Sjogren's syndrome

被引：4

作者：

Andreu Sanchez, Jose Luis ^{[1
]}

Fernandez Castro, Monica ^{[2
]}

del Campo Fontecha, Petra Diaz ^{[3
]}

Corominas, Hector ^{[4
,5
]}

Narvaez Garcia, Francisco Javier ^{[6
]}

Gomez de Salazar, Jose Rosas ^{[7
]}

Rua-Figueroa, Inigo ^{[8
]}

Abad Hernandez, Miguel Angel ^{[9
]}

Alvarez Rivas, Maria Noelia ^{[10
]}

del Pino Montes, Javier ^{[11
]}

Francisco Hernandez, Felix Manuel ^{[8
]}

Gantes Pedraza, Maria Angeles ^{[9
]}

Greco Merino, Martin Gerardo ^{[8
]}

Vanesa Hernandez, Maria ^{[12
]}

Navarro Compan, Maria Victoria ^{[13
]}

Paz Solarte, Juan Alberto ^{[14
]}

Romero Bueno, Fredeswinda, I ^{[15
]}

Park, Hye Sang ^{[16
]}

Sivera Mascaro, Francisca ^{[17
]}

机构：

[1] Hosp Univ Puerta Hierro Majadahonda, Serv Reumatol, Madrid, Spain

[2] Hosp Univ Infanta Sofia, Serv Reumatol, Madrid, Spain

[3] Soc Espanola Reumatol, Unidad Invest, Madrid, Spain

[4] Hosp Univ Santa Creu & St Pau, Unitat Terr Reumatol, Barcelona, Spain

[5] Hosp Dos Maig, Barcelona, Spain

[6] Hosp Univ Bellvitge, Serv Reumatol, Lhospitalet De Llobregat, Spain

[7] Hosp Marina Baixa, Serv Reumatol, Alicante, Spain

[8] Hosp Univ Dr Negrin, Serv Reumatol, Las Palmas Gran Canaria, Spain

[9] Hosp Virgen Puerto, Serv Reumatol, Plasencia, Spain

[10] Hosp Lucus Augusti Lugo, Serv Reumatol, Lugo, Spain

[11] Hosp Univ Salamanca, Serv Reumatol, Salamanca, Spain

[12] Hosp Univ Canarias, Serv Reumatol, Santa Cruz De Tenerife, Spain

[13] Hosp Univ La Paz, Serv Reumatol, Madrid, Spain

[14] Hosp Clin Univ Valencia, Serv Reumatol, Valencia, Spain

[15] Fdn Jimenez Diaz, Serv Reumatol, Madrid, Spain

[16] Hosp Santa Creu & Sant Pau, Serv Reumatol, Barcelona, Spain

[17] Hosp Univ Elda, Serv Reumatol, Alicante, Spain

来源：

REUMATOLOGIA CLINICA | 2019年 / 15卷 / 06期

关键词：

Sjogren's syndrome; Biological therapy; Etanercept; Infliximab; Rituximab; Belimumab; Abatacept; Tocilizumab; Spanish Society of Rheumatology; Recommendations; DOUBLE-BLIND; DISEASE-ACTIVITY; CONTROLLED-TRIAL; CLASSIFICATION CRITERIA; INTERLEUKIN-6; LEVELS; RITUXIMAB TREATMENT; PHASE-III; EFFICACY; SALIVARY; BELIMUMAB;

D O I：

10.1016/j.reuma.2018.10.014

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Objective: To formulate SER recommendations for the use of biological agents in primary Sjogren's syndrome (pSS). Methods: Relevant clinical research questions were identified on the use of biological agents in pSS. The clinical questions were reformulated into 4 PICO questions. A search strategy was designed and a review of the scientific evidence of studies published until May 2017 was carried out. The scientific evidence available was systematically reviewed. The overall level of scientific evidence was assessed using the SIGN evidence levels. After that, specific recommendations were made. Results: Rituximab is recommended as the biological agent of choice for extraglandular manifestations refractory to conventional treatment. The use of anti-TNF agents is discouraged. The scientific evidence with belimumab and abatacept is scarce, so they should be considered only in cases refractory to rituximab. Conclusions: Rituximab is the biological agent of choice in severe extraglandular manifestations of pSS. Belimumab or abatacept may be useful in selected cases. (C) 2018 Elsevier Espana, S.L.U. and Sociedad Espanola de Reumatologia y Colegio Mexicano de Reumatologia. All rights reserved.

引用

页码：315 / 326

页数：12

共 76 条

[1]

Evaluation of Histologic, Serologic, and Clinical Changes in Response to Abatacept Treatment of Primary Sjogren's Syndrome: A Pilot Study [J].

Adler, Sabine ;

Koerner, Meike ;

Foerger, Frauke ;

Huscher, Doerte ;

Caversaccio, Marco-Domenico ;

Villiger, Peter M. .

ARTHRITIS CARE & RESEARCH, 2013, 65 (11) :1862-1868

[2]

A case for IL-6, IL-17A, and nitric oxide in the pathophysiology of Sjogren's syndrome [J].

Benchabane, Sarah ;

Boudjelida, Abdelhalim ;

Toumi, Ryma ;

Belguendouz, Houda ;

Youinou, Pierre ;

Touil-Boukoffa, Chafia .

INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2016, 29 (03) :386-397

[3]

Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjogren's Syndrome [J].

Bowman, Simon J. ;

Everett, Colin C. ;

O'Dwyer, John L. ;

Emery, Paul ;

Pitzalis, Costantino ;

Ng, Wan-Fai ;

Pease, Colin T. ;

Price, Elizabeth J. ;

Sutcliffe, Nurhan ;

Gendi, Nagui S. T. ;

Hall, Frances C. ;

Ruddock, Sharon P. ;

Fernandez, Catherine ;

Reynolds, Catherine ;

Hulme, Claire T. ;

Davies, Kevin A. ;

Edwards, Christopher J. ;

Lanyon, Peter C. ;

Moots, Robert J. ;

Roussou, Euthalia ;

Giles, Ian P. ;

Sharples, Linda D. ;

Bombardieri, Michele .

ARTHRITIS & RHEUMATOLOGY, 2017, 69 (07) :1440-1450

[4]

Systemic activity and mortality in primary Sjogren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients [J].

Brito-Zeron, P. ;

Kostov, B. ;

Solans, R. ;

Fraile, G. ;

Suarez-Cuervo, C. ;

Casanovas, A. ;

Rascon, F. J. ;

Qanneta, R. ;

Perez-Alvarez, R. ;

Ripoll, M. ;

Akasbi, M. ;

Pinilla, B. ;

Bosch, J. A. ;

Nava-Mateos, J. ;

Diaz-Lopez, B. ;

Morera-Morales, M. L. ;

Gheitasi, H. ;

Retamozo, S. ;

Ramos-Casals, M. .

ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (02) :348-355

[5]

Sjogren syndrome [J].

Brito-Zeron, Pilar ;

Baldini, Chiara ;

Bootsma, Hendrika ;

Bowman, Simon J. ;

Jonsson, Roland ;

Mariette, Xavier ;

Sivils, Kathy ;

Theander, Elke ;

Tzioufas, Athanasios ;

Ramos-Casals, Manuel .

NATURE REVIEWS DISEASE PRIMERS, 2016, 2

[6]

Efficacy and safety of rituximab treatment in early primary Sjogren's syndrome: a prospective, multi-center, follow-up study [J].

Carubbi, Francesco ;

Cipriani, Paola ;

Marrelli, Alessandra ;

Di Benedetto, Paola ;

Ruscitti, Piero ;

Berardicurti, Onorina ;

Pantano, Ilenia ;

Liakouli, Vasiliki ;

Alvaro, Saverio ;

Alunno, Alessia ;

Manzo, Antonio ;

Ciccia, Francesco ;

Gerli, Roberto ;

Triolo, Giovanni ;

Giacomelli, Roberto .

ARTHRITIS RESEARCH & THERAPY, 2013, 15 (05)

[7]

Advances in the treatment of ocular dryness associated with Sjogren's syndrome [J].

Ciurtin, Coziana ;

Ostas, Anca ;

Cojocaru, Viorica M. ;

Walsh, Stephen B. ;

Isenberg, David A. .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 2015, 45 (03) :321-327

[8]

B cells in Sjogren's syndrome: From pathophysiology to diagnosis and treatment [J].

Cornec, Divi ;

Devauchelle-Pensec, Valerie ;

Tobon, Gabriel J. ;

Pers, Jacques-Olivier ;

Jousse-Joulin, Sandrine ;

Saraux, Alain .

JOURNAL OF AUTOIMMUNITY, 2012, 39 (03) :161-167

[9]

Treatment of primary Sjogren's syndrome with low-dose human interferon alfa administered by the oromucosal route: Combined phase III results [J].

Cummins, MJ ;

Papas, A ;

Kammer, GM ;

Fox, PC .

ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2003, 49 (04) :585-593

[10]

Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study [J].

Dass, S. ;

Bowman, S. J. ;

Vital, E. M. ;

Ikeda, K. ;

Pease, C. T. ;

Hamburger, J. ;

Richards, A. ;

Rauz, S. ;

Emery, P. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (11) :1541-1544

← 1 2 3 4 5 6 7 8 →